NPORT-EX 2 hatteras-vcci.htm SCHEDULE OF INVESTMENTS AND NOTES


HATTERAS VC CO-INVESTMENT FUND II, LLC
 
(A Delaware Limited Liability Company)
 
SCHEDULE OF INVESTMENTS
 
March 31, 2020 (Unaudited)
 
                     
Descriptions of Investment
Initial Investment Date
 
Cost
   
Fair Value
   
% of Members' Capital
 
                     
Private Company:
                   
Healthcare:
                   
Clinipace, Inc. (1)(2)(3)
                   
Raleigh, North Carolina
                   
100,158 shares of
                   
  Series I Preferred Stock
Sep. 2011
   
500,000
     
188,487
     
13.99
%
Total Healthcare
     
500,000
     
188,487
     
13.99
%
                           
Medical Technology:
                         
Lineagen, Inc. (1)(2)(3)
                         
Salt Lake City, Utah
                         
336,117 shares of
                         
  Series B Preferred Stock
Jul. 2011
   
300,000
     
-
     
0.00
%
                           
Lineagen, Inc. (1)(2)(3)
                         
Salt Lake City, Utah
                         
266,003 shares of
                         
  Series C Preferred Stock
Nov. 2013
   
266,003
     
-
     
0.00
%
Total Medical Technology
     
566,003
     
-
     
0.00
%
                           
Software:
                         
Kollective Technology.  (1)(2)(3)
                         
Sunnyvale, California
                         
45,670 shares of
                         
  Common Stock
Jan. 2012
   
-
     
7,764
     
0.58
%
                           
Kollective Technology.  (1)(2)(3)
                         
Sunnyvale, California
                         
333,334 shares of
                         
  Series B Preferred Stock
Jul. 2010
   
250,000
     
56,667
     
4.21
%
                           
Kollective Technology.  (1)(2)(3)
                         
Sunnyvale, California
                         
1,361,147 shares of
                         
  Series C Preferred Stock
Jan. 2012
   
480,193
     
231,395
     
17.18
%
                           
Posit Science Corporation (1)(2)(3)
                         
San Fransisco, California
                         
80,515 shares of
                         
  Common Stock
Dec. 2009
   
200,000
     
34,750
     
2.58
%
                           
Posit Science Corporation (1)(2)(3)
                         
San Fransisco, California
                         
21,429 shares of
                         
  Series AA Preferred Stock
Sep. 2010
   
11,893
     
9,248
     
0.69
%
                           
Univa Corporation (1)(2)(3)
                         
Austin, Texas
                         
939,541 shares of
                         
  Series I Preferred Stock
Oct. 2010
   
432,114
     
232,309
     
17.24
%
                           
Univa Corporation (1)(2)(3)
                         
Austin, Texas
                         
20,084 shares of
                         
  Series II- A Preferred Stock
Oct. 2010
   
32,536
     
80,945
     
6.01
%
                           
Univa Corporation (1)(2)(3)
                         
Austin, Texas
                         
47,853 shares of
                         
  Series II - B Preferred Stock
Oct. 2010
   
65,894
     
141,562
     
10.51
%
Total Software
     
1,472,630
     
794,640
     
58.98
%
                           
Total Investments in Private Companies (United States)
   
2,538,633
     
983,127
     
72.97
%
                           
Other Assets in excess of Liabilities
             
364,089
     
27.03
%
                           
Members' Capital
             
1,347,216
     
100.00
%
                           
(1) Non-income producing.
                         
(2) Portfolio holdings are subject to substantial restrictions as to resale.
                       
(3) Non-marketable securities
                         
                           
The cost and fair value of restricted Private Company investments are $2,538,633 and $983,127, respectively.
         

 



The Fund classifies its assets into three levels based on the lowest level of input that is significant to the fair value measurement. The three-tier hierarchy distinguishes between (1) inputs that reflect the assumptions market participants would use in pricing an asset or liability developed based on market data obtained from sources independent of the reporting entity (observable inputs) and (2) inputs that reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing an asset or liability developed based on the best information available in the circumstances (unobservable inputs) and to establish classification of fair value measurements for disclosure purposes. Various inputs are used in determining the value of the Fund’s investments.

The inputs are summarized in the three broad levels listed below:


Valuation of Investments

Level 1 – quoted prices (unadjusted) in active markets for identical assets and liabilities

Level 2 – other significant observable inputs (including quoted prices for similar investments, interest rates, prepayment speeds, credit risk, etc.)

Level 3 – significant unobservable inputs (including the Fund’s own assumptions in determining the fair value of investments)

   
Level 1
   
Level 2
   
Level 3
   
Total
 
Private Company1
                       
   Preferred Stock
   
-
     
-
     
940,613
     
940,613
 
   Common Stock
   
-
     
-
     
42,514
     
42,514
 
     Total
 
$
-
   
$
-
   
$
983,127
   
$
983,127
 
                                 
1 All private companies held in the Fund are level 3 securites. For a detailed break-out of private companies by industry classifications, please refer to the Schedule of Investments.
 


   
Preferred Stock
   
Common Stock
   
Total
 
Balance as of July 1, 2019
 
$
2,195,691
   
$
11,352
   
$
2,207,043
 
   Net Realized Gain/(Loss)
   
-
     
-
     
-
 
   Change in Unrealized Appreciation/(Depreciation)
   
(1,255,078
)
   
31,162
     
(1,223,916
)
   Transfers In/(Out) of Investment Categories*
   
-
     
-
     
-
 
   Gross Purchases
   
-
     
-
     
-
 
   Gross Sales
   
-
     
-
     
-
 
Balance as of March 31, 2020
 
$
940,613
   
$
42,514
   
$
983,127
 
                         
* Transfers in or out of investment categories relfect changes in investment categories and are represented by their balance at the beginning of the period.
 
                         
Change in unrealized depreciation attributable to Level 3 investments held as of the reporting date is $1,223,916.
 




The following is a summary of quantitative information about significant unobservable input used for Level 3 fair value measurements for investments held as of March 31, 2020
                   
                   
Type of Investment
Fair Value as of March 31, 2020
 
Valuation Technique
 
Unobservable Input
Weighted Average
 
Range
Impact to valuation from an Increase in Input
Preferred Stock
752,126
 
Market Comparable Companies
 
Forward Revenue Multiple
2.25x
 
1.50x-3.03x
Increase
 
188,487
 
Most Recent Capitalization
 
Private Financing
N/A
 
N/A
N/A
                   
Common Stock
42,514
 
Market Comparable Companies
 
Forward Revenue Multiple
2.58x
 
2.00x-3.03x
Increase
                   
Total Investments
983,127
               

Investments in private companies are generally valued using most recent capitalization technique and market comparable companies techniques. The significant unobservable input used in the most recent capitalization technique is private financing. Two significant unobservable inputs used in the market comparable companies technique is the particular type of market multiple relied upon and a discount rate. Different types of multiples (e.g., forward revenue multiple) are relied upon across the Fund’s portfolio. A significant decrease in one of these multiples in isolation would result in a significantly lower fair value measurement. A significant increase in the discount rate in isolation would result in a significantly lower fair value measurement.

The significant unobservable inputs used in the fair value measurement of the Fund's convertible promissory notes are the likelihood that cash flows or shares will not be received in the future. Significant increases in the probability of default for these securities would result in a lower fair value measurement. The significant unobservable inputs used in the fair value measurement of the Fund's preferred and common stock are generally the financial results of privately held entities. If the financial condition of these companies were to deteriorate, or if market comparables were to fall, the value of the preferred stock or common stock in these private companies held by the Fund would be lower.

The Fund's valuation procedures have been approved by and are subject to continued oversight by the Fund's Board of Managers (the “Board”). The valuation procedures are implemented by the Adviser and the Fund's third party administrator, which report to the Board. For third-party information, the Fund's administrator monitors and reviews the methodologies of the various pricing services employed by the Fund.